These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

602 related articles for article (PubMed ID: 20067390)

  • 1. Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007).
    Snydman DR; Jacobus NV; McDermott LA; Golan Y; Hecht DW; Goldstein EJ; Harrell L; Jenkins S; Newton D; Pierson C; Rihs JD; Yu VL; Venezia R; Finegold SM; Rosenblatt JE; Gorbach SL
    Clin Infect Dis; 2010 Jan; 50 Suppl 1():S26-33. PubMed ID: 20067390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Susceptibility trends of Bacteroides fragilis group isolates from Buenos Aires, Argentina.
    Fernández Canigia L; Castello L; Di Martino A; Greco G; Legaria MC; Litterio M; Predari SC; Rollet R; Rossetti A; Carloni G; Sarchi MI; Bianchini H
    Rev Argent Microbiol; 2007; 39(3):156-60. PubMed ID: 17987852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
    Snydman DR; Jacobus NV; McDermott LA; Ruthazer R; Golan Y; Goldstein EJ; Finegold SM; Harrell LJ; Hecht DW; Jenkins SG; Pierson C; Venezia R; Yu V; Rihs J; Gorbach SL
    Antimicrob Agents Chemother; 2007 May; 51(5):1649-55. PubMed ID: 17283189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
    Snydman DR; Jacobus NV; McDermott LA
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4492-6. PubMed ID: 18838581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. National survey on the susceptibility of Bacteroides Fragilis Group: report and analysis of trends for 1997-2000.
    Snydman DR; Jacobus NV; McDermott LA; Ruthazer R; Goldstein EJ; Finegold SM; Harrell LJ; Hecht DW; Jenkins SG; Pierson C; Venezia R; Rihs J; Gorbach SL
    Clin Infect Dis; 2002 Sep; 35(Suppl 1):S126-34. PubMed ID: 12173121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bacteroides fragilis group in non-diarrheal human feces and its antimicrobial susceptibility].
    Rodríguez E; Gamboa MM; Rodríguez C; Vargas P
    Rev Esp Quimioter; 2006 Dec; 19(4):357-62. PubMed ID: 17235405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006-2009.
    Snydman DR; Jacobus NV; McDermott LA; Golan Y; Goldstein EJ; Harrell L; Jenkins S; Newton D; Pierson C; Rosenblatt J; Venezia R; Gorbach SL; Queenan AM; Hecht DW
    Anaerobe; 2011 Aug; 17(4):147-51. PubMed ID: 21664469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe: 20 years of experience.
    Nagy E; Urbán E; Nord CE;
    Clin Microbiol Infect; 2011 Mar; 17(3):371-9. PubMed ID: 20456453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First national survey of antibiotic susceptibility of the Bacteroides fragilis group: emerging resistance to carbapenems in Argentina.
    Fernández-Canigia L; Litterio M; Legaria MC; Castello L; Predari SC; Di Martino A; Rossetti A; Rollet R; Carloni G; Bianchini H; Cejas D; Radice M; Gutkind G;
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1309-14. PubMed ID: 22232282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance trends of Bacteroides fragilis group over an 8-year period, 1997-2004, in Korea.
    Roh KH; Kim S; Kim CK; Yum JH; Kim MS; Yong D; Lee K; Kim JM; Chong Y
    Korean J Lab Med; 2009 Aug; 29(4):293-8. PubMed ID: 19726890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [ESBL-positive strains of the Bacteroides fragilis group isolated from patients at the regional hospital center in Płock (Poland)].
    Rokosz A; Pawłowska J; Sawicka-Grzelak A; Luczak M
    Med Dosw Mikrobiol; 2004; 56(3):245-53. PubMed ID: 15773501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moxifloxacin resistance is prevalent among Bacteroides and Prevotella species in Greece.
    Papaparaskevas J; Pantazatou A; Katsandri A; Houhoula DP; Legakis NJ; Tsakris A; Avlamis A
    J Antimicrob Chemother; 2008 Jul; 62(1):137-41. PubMed ID: 18385145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of tigecycline against Bacteroides species.
    Betriu C; Culebras E; Gómez M; Rodríguez-Avial I; Picazo JJ
    J Antimicrob Chemother; 2005 Aug; 56(2):349-52. PubMed ID: 15951353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evolution of the sensitivity of Bacteroides group fragilis at the Sevilla University Hospital (1983-1987)].
    Borobio MV; Domínguez MC; Pallares JA; Perea EJ
    Enferm Infecc Microbiol Clin; 1991 Apr; 9(4):214-8. PubMed ID: 1863620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicentre survey of the in-vitro activity of seven antimicrobial agents, including ertapenem, against recently isolated Gram-negative anaerobic bacteria in Greece.
    Papaparaskevas J; Pantazatou A; Katsandri A; Legakis NJ; Avlamis A;
    Clin Microbiol Infect; 2005 Oct; 11(10):820-4. PubMed ID: 16153256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial susceptibility of clinical isolates of Bacteroides fragilis group organisms recovered from 2009 to 2012 in a Korean hospital.
    Yim J; Lee Y; Kim M; Seo YH; Kim WH; Yong D; Jeong SH; Lee K; Chong Y
    Ann Lab Med; 2015 Jan; 35(1):94-8. PubMed ID: 25553287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibiotic sensitivity of the Bacteroides fragilis group in Denmark. Danish Study Group.
    Bremmelgaard A; Jansen JE; Justesen T; Gottschau A
    APMIS; 1993 Sep; 101(9):727-31. PubMed ID: 8240792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility trends of Bacteroides fragilis group and characterisation of carbapenemase-producing strains by automated REP-PCR and MALDI TOF.
    Treviño M; Areses P; Peñalver MD; Cortizo S; Pardo F; del Molino ML; García-Riestra C; Hernández M; Llovo J; Regueiro BJ
    Anaerobe; 2012 Feb; 18(1):37-43. PubMed ID: 22261518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surveillance and trends of antimicrobial resistance among clinical isolates of anaerobes in Kuwait hospitals from 2002 to 2007.
    Jamal W; Shahin M; Rotimi VO
    Anaerobe; 2010 Feb; 16(1):1-5. PubMed ID: 19406247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole.
    Goldstein EJ; Citron DM; Cherubin CE; Hillier SL
    J Antimicrob Chemother; 1993 Mar; 31(3):363-72. PubMed ID: 8486570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.